Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors

    SAN FRANCISCO, Aug. 21 /CNW/ -- Medizone International, Inc. (Pink
Sheets: MZEI) announces the appointment of Michael E. Shannon, M.A., M.Sc.,
M.D. to its Board of Directors.  Dr. Shannon received his medical degree from
Queen's University in Canada, which included advanced training in surgery and
sports medicine.  He also holds post-graduate degrees in neurochemistry and
physiology.  He has been actively engaged in applied medical research within
these areas for over 27 years.  He served in the Canadian Forces for 31 years
retiring at the rank of Commodore (Brigadier General equivalent) as Deputy
Surgeon General for Canada.  During the first Gulf War, Dr. Shannon served as
the senior medical liaison officer for all of the Canadian forces.  In 1996 he
assumed responsibilities within Health Canada for re-organizing the Canadian
blood system.  Working with both the provincial and federal governments, he
oversaw the development of a new corporate entity dedicated exclusively to the
management of blood services in Canada.  He was then appointed Director
General for the Laboratory Centre for Disease Control, a position he held for
three years.  In December 2000, Dr. Shannon left the Canadian federal
government to pursue a new career in industry.  In that capacity he
simultaneously directed a phase III clinical trial in Canada, the United
States and Great Britain for an artificial blood substitute product. Following
completion of that work he was asked to accept a special assignment with the
Canadian Federal Government Auditor General's office.  His assignment was to
conduct a cost benefit analysis of all government sponsored pharmacare
programs and make recommendations directly to the Parliament of Canada.  His
assignment and presentation to Parliament on that project was completed in
November 2004.  Dr. Shannon recently worked on a special project assignment as
Senior Medical Advisor to the Canadian Public Health Agency.  His assignment
was to review and help rebuild the Canadian Public Health Agency's Emergency
Medical Response Capacity.  His work in that regard with the Canadian
government was completed the end of July this year.
    Internationally respected for his expertise, Dr. Shannon has been
actively engaged in medical bio-oxidative (O3 based), research since 1987 and
was directly responsible for the first human clinical trial to have ever been
approved in North America which examined the efficacy of O3 delivered via
autohemotherapy in the treatment of AIDS.  He was also responsible for several
primate studies utilizing O3 involving scientists from various departments
within the Canadian Federal Government, as well as senior investigators from
Medizone International and Cornell University.
    Medizone's Chairman and CEO, Edwin Marshall commented; "On behalf of the
members of the board and all of the Company's shareholders, we welcome Dr.
Shannon to our Board of Directors.  The wisdom and expertise Dr. Shannon
brings to Medizone is unparalleled in the history of our company.  I consider
him a remarkable man and feel honored to be able to refer to him as a
professional associate.  This appointment signals an immense step forward in
the reorganization of Medizone International.
    Medizone International, Inc., is a research and development stage company
engaged in the development of patented and unpatented technologies and
protocols for O3 based bio-oxidative treatment of diseases caused by lipid
enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS),
Hepatitis B & C, and Herpes, the decontamination of blood, blood products and
veterinarian serum products, and the treatment of external pathogenic
    This Press Release contains certain forward looking statements that
involve substantial risks and uncertainties, including, but not limited to,
the results of ongoing clinical studies, economic conditions, product and
technology development, production efficiencies, product demand, competitive
products, competitive environment, successful testing and government
regulatory issues.  Additional risks are identified in the company's filings
made with the Securities and Exchange Commission.

For further information:

For further information: Operations at Medizone, +1-415-868-0300, Web Site:

Organization Profile

Medizone International, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890